Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 3/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.32 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24711724 | 0.82 | SMN1; SMN2 (0.44) | SMN1; SMN2TSHRSLC6A9HRH3MAPT | |
| SCHEMBL26241194 | 0.79 | SMN1; SMN2 (0.37) | SMN1; SMN2TSHRDPP4PREPFAP | |
| SCHEMBL24711535 | 0.79 | SMN1; SMN2 (0.37) | SMN1; SMN2TSHRPRKCBSLC6A9HRH3 | |
| SCHEMBL20008957 | 0.78 | SMN1; SMN2 (0.41) | SMN1; SMN2TSHRDPP4PRKCBSLC6A9 | |
| SCHEMBL16869402 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2TSHRPRKCBSLC6A9HRH3 | |
| SCHEMBL27157659 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2TSHRPRKCBSLC6A9HRH3 | |
| SCHEMBL20009022 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2TSHRPRKCBSLC6A9HRH3 | |
| SCHEMBL27204244 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2TSHRPRKCBSLC6A9HRH3 | |
| SCHEMBL20008992 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2TSHRPRKCBSLC6A9HRH3 | |
| SCHEMBL20008949 | 0.76 | HRH3 (0.38) | SMN1; SMN2TSHRPRKCBSLC6A9HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-06-04 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10308614-B2 | Therapeutic compounds and uses thereof | SMARCC1, SMARCC2, SMARCA4 | SMN1; SMN2 176/4885TSHR 1817/4885DPP4 4453/4885 |
| US-20180086720-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | SMARCC1, SMARCC2, SMARCA4 | SMN1; SMN2 176/4885TSHR 1817/4885DPP4 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.